Gene Therapy

February 4, 2019

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

October 24, 2018
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam's Thirty Year Journey to First Approval

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

October 10, 2018
Global Drug Development IPOs: 26 Companies Raise $3.18B in Q3 as First Pre-Revenue Biotechs List on HKEX

Global Drug Development IPOs: 26 Companies Raise $3.18B in Q3 as First Pre-Revenue Biotechs List on HKEX

July 12, 2018
Global Drug Development IPOs: NASDAQ Dominance Continues as 26 Companies Raise Over $2.54B in Q2

Global Drug Development IPOs: NASDAQ Dominance Continues as 26 Companies Raise Over $2.54B in Q2

April 12, 2018
Lonza Opens World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas

Lonza Opens World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas

February 20, 2018
2018 Global Drug Development IPO Review

2018 Global Drug Development IPO Analysis: $10.24B Raised in Strongest Year on Record

January 30, 2018
GLOBAL DRUG DEVELOPMENT IPOs: $6.4B Raised as Bullish Investors Back Biologics & Gene Therapies Despite Slowed Growth in 2017

Global Therapeutic IPO Review: $6.4B Raised as Bullish Investors Back Biologics & Gene Therapies Despite Slowed Growth in 2017

January 23, 2018
Gene Therapy Manufacturing: An Impending Crisis or Temporary Growing Pains?

Gene Therapy Manufacturing: An Impending Crisis or Temporary Growing Pains?

October 24, 2017
Monogenic Gene Therapies: Will Spark Therapeutics’ Luxturna Avoid the Fate of Glybera & Strimvelis?

Monogenic Gene Therapies: Will Spark Therapeutics’ Luxturna Avoid the Fate of Glybera & Strimvelis?

Contact Us